Tumor therapies have entered the immunotherapy era. Immune checkpoint inhibitors have achieved tremendous success, with some patients achieving long-term tumor control. Tumors, on the other hand, can still accomplish immune evasion, which is aided by immune checkpoints. The majority of immune checkpoints are membrane glycoproteins, and abnormal tumor glycosylation may alter how the immune system perceives tumors, affecting the body’s anti-tumor immunity. Furthermore, RNA can also be glycosylated, and GlycoRNA is important to the immune system. Glycosylation has emerged as a new hallmark of tumors, with glycosylation being considered a potential therapeutic approach. The glycosylation modification of immune checkpoints and the most recent advances in glycosylation-targeted immunotherapy are discussed in this review.

中文翻译：

---

免疫检查点的糖基化及其在肿瘤学中的应用

肿瘤治疗已进入免疫治疗时代。免疫检查点抑制剂取得了巨大成功，一些患者实现了肿瘤的长期控制。另一方面，肿瘤仍然可以在免疫检查点的帮助下完成免疫逃避。大多数免疫检查点是膜糖蛋白，异常的肿瘤糖基化可能会改变免疫系统感知肿瘤的方式，影响机体的抗肿瘤免疫力。此外，RNA也可以被糖基化，而GlycoRNA对免疫系统很重要。糖基化已成为肿瘤的新标志，糖基化被认为是一种潜在的治疗方法。本综述讨论了免疫检查点的糖基化修饰以及糖基化靶向免疫治疗的最新进展。